{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:57:42Z","timestamp":1789689462069,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.003","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T08:31:00Z","timestamp":1596011460000},"page":"849-859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed?"],"prefix":"10.1016","volume":"34","author":[{"given":"Jason T.","family":"Romancik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hoc.2020.06.003_bib1","first-page":"443","article-title":"2016\u00a0US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.003_bib2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bjh.14699","article-title":"Incidence and survival trends in mantle cell lymphoma","volume":"181","author":"Epperla","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.003_bib3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.003_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.003_bib5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2020.06.003_bib6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.003_bib7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10121","key":"10.1016\/j.hoc.2020.06.003_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.003_bib9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"issue":"68","key":"10.1016\/j.hoc.2020.06.003_bib10","doi-asserted-by":"crossref","first-page":"112516","DOI":"10.18632\/oncotarget.22367","article-title":"Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.003_bib11","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2012.760041","article-title":"An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA","volume":"54","author":"Aschebrook-Kilfoy","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.003_bib12","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2012.656628","article-title":"Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007","volume":"53","author":"Chandran","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.003_bib13","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.003_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"Tsukamoto","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.003_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ajh.22126","article-title":"Utility of positron emission tomography scans in mantle cell lymphoma","volume":"86","author":"Hosein","year":"2011","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.003_bib16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.003_bib17","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/01.pas.0000208899.15859.cb","article-title":"Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study","volume":"30","author":"Salar","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2020.06.003_bib18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jcp.2005.030783","article-title":"In situ-like\" mantle cell lymphoma: a report of two cases","volume":"59","author":"Richard","year":"2006","journal-title":"J\u00a0Clin Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.003_bib19","doi-asserted-by":"crossref","first-page":"E333","DOI":"10.1002\/hed.23206","article-title":"In situ mantle cell lymphoma in the nasopharynx","volume":"35","author":"Koletsa","year":"2013","journal-title":"Head Neck"},{"issue":"15","key":"10.1016\/j.hoc.2020.06.003_bib20","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1182\/blood-2010-10-299628","article-title":"How I treat: diagnosing and managing \"in situ\" lymphoma","volume":"117","author":"Carbone","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.003_bib21","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/modpathol.2012.117","article-title":"Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in\u00a0situ in reactive lymphoid tissues","volume":"25","author":"Adam","year":"2012","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.003_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3324\/haematol.2011.052621","article-title":"In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior","volume":"97","author":"Carvajal-Cuenca","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.003_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2020.06.003_bib24","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.003_bib25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/bjc.1994.213","article-title":"Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy","volume":"69","author":"Vaughan Hudson","year":"1994","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.003_bib26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0360-3016(99)00051-6","article-title":"The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma","volume":"44","author":"Kamath","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.003_bib27","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for Stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.hoc.2020.06.003_bib28","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.hoc.2020.06.003_bib29","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014","volume":"26","author":"Persky","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"10216","key":"10.1016\/j.hoc.2020.06.003_bib30","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.003_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1182\/blood-2019-123871","article-title":"PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001","volume":"134","author":"Persky","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.003_bib32","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.003_bib33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1200\/JOP.0758501","article-title":"How I treat mantle cell lymphoma","volume":"3","author":"Straus","year":"2007","journal-title":"J\u00a0Oncol Pract"},{"issue":"9","key":"10.1016\/j.hoc.2020.06.003_bib34","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.6004\/jnccn.2014.0125","article-title":"Non-Hodgkin's lymphomas, version 4.2014","volume":"12","author":"Zelenetz","year":"2014","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.003_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.hemonc.2017.02.003","article-title":"Mantle cell lymphoma: contemporary diagnostic and treatment perspectives in the age of personalized medicine","volume":"10","author":"Sandoval-Sus","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"39","key":"10.1016\/j.hoc.2020.06.003_bib36","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1038\/sj.onc.1206826","article-title":"Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma","volume":"22","author":"M'Kacher","year":"2003","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.003_bib37","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1365-2141.1997.4693273.x","article-title":"The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group","volume":"99","author":"Vandenberghe","year":"1997","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.003_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s002770050545","article-title":"Management of mantle cell lymphoma","volume":"78","author":"Meusers","year":"1999","journal-title":"Ann Hematol"},{"issue":"Suppl","key":"10.1016\/j.hoc.2020.06.003_bib39","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.clml.2014.04.013","article-title":"Effect of radiotherapy on the survival of patients with stage I and stage II mantle cell lymphoma: analysis of the Surveillance, Epidemiology and End Results database","volume":"14","author":"Guru Murthy","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.003_bib40","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2006.02.011","article-title":"Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)","volume":"65","author":"Rosenbluth","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.003_bib41","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.003_bib42","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.06.003_bib43","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/cncr.30068","article-title":"Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma","volume":"122","author":"Cohen","year":"2016","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2020.06.003_bib44","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/annonc\/mdx334","article-title":"Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"28","author":"Dabaja","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.003_bib45","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.003_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10428194.2012.711828","article-title":"Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital","volume":"54","author":"Bernard","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.003_bib47","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00277-019-03803-x","article-title":"Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: consortium for improving survival of lymphoma report","volume":"99","author":"Jo","year":"2020","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.003_bib48","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijrobp.2015.07.2265","article-title":"Management trends and outcomes for stage I to II mantle cell lymphoma using the national cancer data base: ascertaining the ideal treatment paradigm","volume":"93","author":"Gill","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.003_bib49","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00277-018-3571-7","article-title":"Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?","volume":"98","author":"Chihara","year":"2019","journal-title":"Ann Hematol"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2020.06.003_bib50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1182\/blood-2019-123106","article-title":"EARLY STAGE Follicular Lymphoma: First Results of the FIL \"Miro\" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-driven immunotherapy","volume":"134","author":"Pulsoni","year":"2019","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:18Z","timestamp":1760184858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300666"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed?","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}